Cannabis Bioscience International Holdings, INC

Cannabis Bioscience International Holdings sold 250 million shares to a director, John Jones, for $75,000, with a repurchase agreement if the share value doesn't reach a certain level by the end of 2025.

Cannabis Bioscience International Holdings has appointed Charles Tamburello to its board of directors and established an executive committee with full board authority, subject to certain limitations.

Cannabis Bioscience International Holdings has entered into a master research agreement with Alpha Research Institute and appointed John Jones as a director and treasurer, while also adjusting interest rates on a promissory note.

Cannabis Bioscience International Holdings, Inc. has entered into a Securities Purchase Agreement to issue a $66,000 bridge note to 1800 Diagonal Lending LLC.

Cannabis Bioscience International Holdings reports a net loss of $103,933 for the third quarter ended February 28, 2026, amid ongoing liquidity and going concern challenges.

Cannabis Bioscience International Holdings reports significantly increased net losses and a critical cash position, raising substantial doubt about its ability to continue as a going concern.

Cannabis Bioscience International Holdings, Inc. reported a significant revenue decline and increased net loss, raising substantial doubt about its ability to continue as a going concern.

Cannabis Bioscience International Holdings files an amendment to its Q3 report to correct financial statement errors, update the share count, and include XBRL data.

Cannabis Bioscience International Holdings reports increased revenue for the nine months ended February 28, 2025, but continues to struggle with net losses and a going concern uncertainty.

Cannabis Bioscience International Holdings files an amended 10-Q for the quarter ended November 30, 2024, showing improved revenue and reduced losses compared to the previous year.

Cannabis Bioscience International Holdings, Inc. reported a reduced net loss for fiscal year 2025, driven by increased clinical trial revenue, while facing significant going concern doubts and a need for substantial capital.

Cannabis Bioscience International Holdings' latest 10-K filing reveals a net loss of $651,345 for the fiscal year ending May 31, 2024, and highlights the company's ongoing efforts to navigate financial difficulties and expand its operations.